Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report). The associated price target remains the same with $38.00.
Sam Slutsky has given his Buy rating due to a combination of factors related to ArriVent BioPharma’s promising developments and strategic progress. The company is advancing its clinical trials for firmonertinib, particularly in the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The Phase 3 FURVENT study, which has reached its target enrollment, is anticipated to provide pivotal topline data in 2025, and firmonertinib’s Breakthrough Therapy Designation by the FDA underscores its potential impact.
Additionally, interim results from the Phase 1b FURTHER study show encouraging outcomes in the EGFR PACC mutant NSCLC setting, with high objective response rates that position firmonertinib favorably within the competitive landscape. Despite uncertainties regarding the path to regulatory approval, the unmet clinical needs and the drug’s promising efficacy data contribute to a positive outlook. These factors, combined with the company’s strategic focus and ongoing developments, underpin Slutsky’s Buy recommendation.